Prostacyclin receptor (IP) agonists display anti-inflammatory and anti-viral activity in cell-based assays and in pre-clinical models of asthma and chronic obstructive pulmonary disease. We have extended these observations by demonstrating that IP-receptor activation also can enhance the ability of glucocorticoids to induce genes with anti-inflammatory activity. BEAS-2B bronchial epithelial cells stably transfected with a glucocorticoid response element (GRE) luciferase reporter were activated in a concentration-dependent manner by the glucocorticoid, dexamethasone (p[A] 50 = 7.96 ± 0.11; E max = 19.3 ± 3.8-fold). An IP-receptor agonist, taprostene, increased cAMP in these cells (p[A] 50 = 8.01 ± 0.01) and augmented luciferase expression at all concentrations of dexamethasone examined. Analysis of the concentrationresponse relationship that described this effect showed that taprostene increased the magnitude of transcription (~ 2-fold) without affecting the potency of dexamethasone (p[A] 50 = 7.73 ± 0.2) and was, thus, steroid-sparing in this simple system. RO3244794, an IP-receptor antagonist, and oligonucleotides that selectively silenced the IP-receptor gene, PTGIR, abolished these effects of taprostene. Infection of BEAS-2B GRE reporter cells with an adenovirus vector (Ad5.CMV.PKIα) encoding a highly selective inhibitor of cAMP-dependent protein kinase (PKA) also prevented taprostene from enhancing GRE-dependent transcription. Collectively, these data show that IPreceptor agonists can augment the ability of glucocorticoids to induce anti-inflammatory genes in human airway epithelial cells by activating a cAMP/PKA-dependent mechanism. This observation may have clinical relevance in the treatment of airway inflammatory diseases that are either refractory, or respond sub-optimally, to glucocorticoids.
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